MedSci Healthcare Holdings Limited (MedSci) released its audited results for the year ended 31 December 2025.
Revenue and Profitability • Full-year revenue inched up 3.74% year-on-year to RMB270.37 million, supported by growth in precision omni-channel marketing solutions (+5.87%) and real-world study (RWS) solutions (+20.84%). • Profit attributable to owners of the parent fell 28.16% to RMB17.94 million, reflecting a contraction in gross profit and a sharp drop in other income and gains. • Gross profit slipped 1.07% to RMB160.45 million; gross margin eased to 59.34% from 62.21% a year earlier as cost of sales rose 11.67% to RMB109.93 million. • Earnings per share (basic and diluted) declined to RMB0.03 (2024: RMB0.05). The Board proposed no final dividend.
Segment Performance • Precision omni-channel marketing solutions: Revenue rose to RMB121.85 million, accounting for 45.07% of the total. • Physician platform solutions: Revenue dropped 15.32% to RMB92.96 million amid customer use of AI for certain functions. • RWS solutions: Revenue climbed to RMB43.21 million, buoyed by stronger demand for evidence-based support from pharmaceutical clients. • Data and artificial intelligence solutions, launched during the year, contributed RMB12.36 million, representing 4.57% of total revenue.
Cost Structure and Expenses • Selling and distribution expenses fell 23.30% to RMB60.45 million, reflecting higher sales efficiency and tighter cost controls. • Research and development expenditure rose 32.0% to RMB30.66 million as the company accelerated investment in AI products such as SeekEvidence and DeepEvidence. • Administrative expenses decreased 31.0% to RMB42.23 million after cost-control measures. • Other income and gains declined 70.5% to RMB12.19 million, mainly due to lower bank interest income and the absence of prior-year fair value gains on financial assets.
Balance Sheet and Liquidity • Cash and cash equivalents stood at RMB367.73 million; time deposits and financial assets at fair value through profit or loss totalled RMB819.61 million. • Current assets reached RMB1.35 billion against current liabilities of RMB201.36 million, giving a healthy current ratio of 6.7x. • The Group reported zero bank borrowings and a gearing ratio of nil, with net assets of RMB1.18 billion. • No material capital expenditure, commitments or contingent liabilities were reported.
Strategic Highlights and Outlook MedSci continued to embed AI across product development, content creation and service delivery, positioning its new solutions as growth drivers. Management reiterated focus on three strategic pillars: academically driven precision services, AI-powered innovation, and international expansion. The company expects AI integration and sustained demand for RWS and precision marketing to underpin long-term competitiveness amid evolving pharmaceutical industry reforms.
Dividend Consistent with the prior year, the Board recommended no final dividend for FY2025.